Merispas Tablet is a combination medication containing Dicyclomine 20 mg and Mefenamic Acid 250 mg, indicated for the relief of pain associated with gastrointestinal spasms and inflammatory conditions. Dicyclomine is an anticholinergic agent that acts by inhibiting the muscarinic receptors in the smooth muscles of the gastrointestinal tract, thereby reducing muscle spasms and cramping. Mefenamic Acid is a nonsteroidal anti-inflammatory drug (NSAID) that provides analgesic, anti-inflammatory, and antipyretic effects by inhibiting cyclooxygenase enzymes, leading to decreased prostaglandin synthesis. This combination is particularly effective in managing conditions such as irritable bowel syndrome, dysmenorrhea, and other spasmodic abdominal pain where both muscle relaxation and pain relief are required. Merispas Tablet should be administered as prescribed by a healthcare professional, typically after meals to minimize gastrointestinal discomfort. Caution is advised in patients with a history of peptic ulcers, renal impairment, or hypersensitivity to NSAIDs or anticholinergic agents. Common side effects may include dry mouth, dizziness, nausea, and mild gastrointestinal disturbances. Patients are advised to avoid driving or operating heavy machinery if experiencing dizziness. Consultation with a healthcare provider is essential before initiating therapy to ensure appropriate use and monitoring.